Skip to main content

Welcome to Janssen Canada

VISIT JANSSEN GLOBAL

Title

Media

06, April, 2023

Toronto

RYBREVANT^®(amivantamab) receives positive CADTH reimbursement recommendation for the treatment of adult patients with non-small cell lung cancer with activating EGFR exon 20 insertion mutations

24, March, 2023

Toronto

Health Canada Authorizes IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

04, April, 2022

TORONTO, ON

Janssen Announces Health Canada Approval of RYBREVANT®(amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

24, November, 2021

Toronto

Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 in Individuals 18 years and Older

15, October, 2021

Toronto

OPSYNVI® (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)

13, September, 2021

Toronto

^NSPRAVATO® (esketamine)* Nasal Spray Authorized in Canada, for Short-Term Treatment, for the Rapid Reduction of Depressive Symptoms in Adults with Major Depressive Disorder Requiring Urgent Psychiatric Care

11, June, 2021

Toronto

Johnson & Johnson Statement on Supply of COVID-19 Vaccine Currently on Hold in Canada

19, April, 2021

Toronto

DARZALEX® SC Becomes the First and Only Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis, A Rare Disease

04, March, 2021

Toronto

Johnson & Johnson COVID-19 Vaccine Granted Authorization under Interim Order by Health Canada For Emergency Use

13, January, 2021

Toronto

Health Canada Approves IMBRUVICA^® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)